**e-table 8. Ongoing clinical trials**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Serial**  **number** | **Name of the trial** | **NCT number** | **Sponsor/Collaborators** | **Country** | **Study Design** | **Number enrolled** | **Interventions** | **Outcomes** | **Status** |
| 1 | Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff | NCT04723459 | South Valley University | Egypt | Interventional | 150 | * Ivermectin mask | * Number of persons in each group who Complain of any suspected Symptoms * Number of persons in each group who are diagnosed as COVID-19 patients | Recruiting |
| 2 | Inhaled Ivermectin and COVID-19(CCOVID-19) | NCT04681053 | Mansoura University | Egypt | Interventional | 80 | * Ivermectin Powder | * Rate of virological cure by RT-PCR * Resolution of pneumonia | Recruiting |
| 3 | Ivermectin in the treatment of COVID-19 patients | NCT04723459 | Ministry of Health and Population, Egypt | Egypt | Interventional | 100 | * Ivermectin | * Rate of viral clearance in comparison to other treatment protocols * Evaluate the role of ivermectin as a line of treatment for COVID-19 | Recruiting |
| 4 | An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization | NCT04729140 | Max Health, Subsero Health | USA | Interventional | 150 | * Ivermection, * Doxycycline * Placebo | * Assessment of Hb, WBC, HcT, Platelet Count, Na,Cl,Co2 levels, * Admission rate to the hospital secondary to respiratory illness related to COVID-19, * Total duration of symptoms secondary to respiratory illness related to COVID-19 | Recruiting |
| 5 | COVidIVERmectin: Ivermectin for Treatment of Covid-19 | NCT04438850 | IRCCS Sacro Cuore Don Calabria di Negrar and Istituto Di Ricerche Farmacologiche Mario Negri | Italy and Spain | Interventional | 102 | * Ivermectin * Placebo | * SADR * Viral load * Trend viral load * Clinical resolution * Viral clearance * Virological clearance * Hospitalization rate * Severity score | Recruiting |
| 6 | Ivermectin to Prevent Hospitalizations in COVID-19 | NCT04529525 | Instituto de Cardiología de Corrientes | Argentina | Interventional | 500 | * Ivermectin * Placebo | * Percentage of Hospitalization of medical cause in patients with COVID-19 in each arm * Time to hospitalization * Percentage of use of invasive mechanical support in each arm * Time to invasive mechanical ventilation support * Percentage of dialysis in each arm * All-cause mortality * Negative of the swab at 3±1 days and 12±2 days after entering the study * Incidence of Treatment Emergent Adverse Events | Recruiting |
| 7 | Study in COvid-19 Patients With ivermectin (CORVETTE-01) | NCT04703205 | Kitasato University | Japan | Interventional | 240 | * Ivermectin * Placebo | * Period until the COVID-19 PCR test becomes negative | Recruiting |
| 8 | Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment | NCT04673214 | Gilberto Cruz Arteaga | Mexico | Interventional | 62 | * Azithromycin * Ivermectin * Ribaroxaban * Paracetamol | * Estimate clinical symptoms by days of follow-up * To assess adverse drug reactions by days of follow-up | Recruiting |
| 9 | Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 | NCT04429711 | Sheba Medical Center | Israel | Interventional | 100 | * Ivermectin | * Viral clearance at day 6 * Viral shedding * Duration of Symptoms * Clearance time | Recruiting |
| 10 | Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19 | NCT04716569 | South Valley University | Egypt | Interventional | 150 | * Ivermectin intranasal spray | * Progression of covid 19 clinical picture | Recruiting |
| 11 | Efficacy of Ivermectin in outpatients with non-severe COVID-19 | NCT04834115 | Universidad Nacional de Asuncion | Paraguay | Interventional | 400 | * Ivermectin tablets | * Primary-proportion of patients with hospitalization criteria * Secondary- 1)proportion of patients with COVID-19 signs and symptoms 2)proportion of cohabitants who had COVID-19 after the index case 3)drug-related adverse events 4)Levels of IgG for SARS-CoV-2 | Recruiting |
| 12 | Ivermectin in Adults With Severe COVID-19. | NCT04602507 | CES University | Colombia | Interventional | 100 | * Ivermectin plus routine care | * Admission to the intensive care unit * Hospital length of stay * Mortality rate * ICU length of stay * Length of stay in ventilator time * Adverse effects of ivermectin | Recruiting |
| 13 | Ivermectin as a Novel Therapy in COVID-19 Treatment | NCT04403555 | Tanta University | Egypt | Interventional | 160 | * Ivermectin plus standard of care | * The number of patients with improvement or mortality | Recruiting |
| 14 | Ivermectin in Treatment of COVID-19 | NCT04445311 | Zagazig University | Egypt | Interventional | 100 | * Ivermectin | * Time to be symptoms free * Need hospital admission * Need mechanical ventilation * Length of stay * Mortality | Recruiting |
| 15 | Efficacy of Ivermectin in COVID-19 | NCT04392713 | Combined Military Hospital, Pakistan | Pakistan | Interventional | 100 | * Ivermectin | * Negative PCR * Need for mechanical ventilation | Recruiting |
| 16 | The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment | NCT04351347 | Tanta University | Egypt | Interventional | 300 | * Ivermectin plus Nitazoxanide | * Number of patients with improvement or died | Recruiting |
| 17 | Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study | NCT04373824 | Max Healthcare Institute Limited | India | Interventional | 50 | * Ivermectin | * Effect of ivermectin on the eradication of virus | Recruiting |
| 18 | Repurposed Approved Therapies for Outpatient Treatment of Patients With Early-Onset COVID-19 and Mild Symptoms | NCT04727424 | Cardresearch | Brazil | Interventional | 2724 | * Fluvoxamine Maleate 100 MG [Luvox] * Metformin Extended Release Oral Tablet * Ivermectin Tablets * Placebo | * Change in viral load on day 03 and 07 after randomization * Time to > 50% clinical improvement * Time to hospitalization * Days with symptoms * All cause hospitalizations * COVID-19 hospitalizations * All-Cause Death * Cardiovascular death * Respiratory death * Promis Global-10 scale * WHO ordinal scale for clinical improvement * Percentage of adherence on Study drug | Recruiting |
| 19 | Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19 (IvAzCol) | NCT04399746 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | Mexico | Interventional | 30 | * Ivermectin * Azithromycin * Cholecalciferol | * Viral clearance * Symptoms duration * SpO2, SpO2/FiO2 | Recruiting |
| 20 | Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection (IDRA-COVID19) | NCT04435587 | Mahidol  University | Thailand | Interventional | 80 | * Ivermectin Pill * Combined ART/ hydroxychloroquine | * Adverse event rates * Efficacy for shortening duration of SAR-CoV2 detection by PCR * Antibody detection rates | Recruiting |
| 21 | Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients (SIZI-COVID-PK) | NCT04472585 | Sohaib Ashraf | Pakistan | Interventional | 60 | * Ivermectin Injectable Solution * Injectable Placebo * Zinc * Placebo empty capsule | * Time needed to turn positive COVID-19 PCR to negative * Time taken for alleviation of symptoms * Severity of symptoms * Mortality | Recruiting |
| 22 | Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19 (SAINT-PERU) | NCT04635943 | Universidad Peruana Cayetano Heredia  Barcelona Institute for Global Health | Peru | Interventional | 68 | * Ivermectin * Placebo | * Proportion of patients with a positive SARS-CoV-2 PCR * Mean viral load * Fever and cough progression * Seroconversion at day 21 * Proportion of drug-related adverse events * Levels of IgG, IgM and IgA * Frequency of innate immune cells * Frequency SARS-CoV-2- specific CD4+ and CD8+ T cells * Results from cytokine Human Magnetic 30-Plex Panel * Presence of intestinal helminths | Recruiting |
| 23 | Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN) | NCT04447235 | Instituto do Cancer do Estado de São Paulo | Brazil | Interventional | 176 | * Placebo * Ivermectin * Losartan | * Incidence of severe complications due COVID-19 infection * Incidence of Severe Acute Respiratory Syndrome * Adverse events * Overall survival | Recruiting |
| 24 | Comparative therapeutic efficacy and safety of different antiviral and anti inflammatory drugs in COVID-19 patients | NCT04779047 | Beni-Suef University | Egypt | Interventional | 150 | * Remdesivir * Hydroxychloroquine * Tocilizumab * Lopinavir/ Ritonavir * Ivermectin | * Percentage of clinical cure in each arm | Recruiting |
| 25 | Novel Agents for Treatment of High-risk COVID-19 Positive Patients | NCT04374019 | Susanne Arnold  University of Kentucky | United States | Interventional | 240 | * Ivermectin * Camostat Mesilate * Dietary Supplement: Artemesia annua, Artesunate | * Clinical Deterioration * Change in Viral Load * Rate of Organ Failure * Progression to ICU Care or Ventilation * Change in Clinical Status * Mortality * Rate of severe adverse events * Oxygen-free days * Ventilator-free days * Vasopressor-free days * ICU-free days * Hospital-free days * Patients meeting Hy's Law criteria * Liver Function * Heart Function | Recruiting |
| 26 | Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis | NCT04384458 | Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara | Brazil | Interventional | 400 | * Hydroxychloroquine * Ivermectin | * Proportion of participants in whom there was a positivity for SARS CoV-2 * Participants who developed mild, moderate, or severe forms of COVID-19 * Measurement of the QT interval * Widening of the corrected QT interval or with changes in heart rate on the ECG * Comparison of hematological and biochemical parameters * Occurrence of adverse events * Assessment of COVID-19 symptom severity * Proportion of participants who discontinue study intervention * Proportion of participants who required hospital care * Proportion of participants who required mechanical ventilation. | Recruiting |
| 27 | A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19 | NCT04431466 | Universidade Federal de Sao Carlos | Brazil | Interventional | 64 | * Ivermectin * Standard treatment for COVID-19 | * Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab * Viral load variation in the nasopharyngeal swab * Proportion of patients with undetectable SARSCoV-2 viral load in the nasopharyngeal swab * Proportion of patients with clinical improvement. | Recruiting |
| 28 | Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia | NCT04703608 | London School of Hygiene and Tropical Medicine | Gambia | Interventional | 1200 | * Ivermectin * ASP (Aspirin Parallel Assignment) * Placebo | * Cohort 1 Index Case: Percentage of patients with COVID-19 associated mild disease/moderate pneumonia progressing to severe pneumonia. * Cohort 1 Household contacts: Percentage of HH members that get infected with SARS-CoV-2 * Cohort 2: Percentage of COVID-19 associated severe pneumonia patients worsening their condition * Cohort1 Index cases: Days from recruitment to virological clearance * Days from recruitment until clinical recovery * IgG geometric mean titre (GMT) at day 14 and 28 after recruitment -Household contacts IgG geometric mean titre (GMT) at day 14 after recruitment  -Percentage of HH members infected that develop COVID19 symptoms  -Cohort 2 - Hours from recruitment to hospital discharge -Hours of duration on oxygen supplementation * Death ratio during hospitalization * Death ratio at D28 and D90 * Occurrence of clinical thrombotic and embolic events * Occurrence of clinical episodes of gastrointestinal bleeding * Change in CRP and D-Dimer levels * Persisting breathlessness at 28 days and 90 days after * Self-reported health at 28 days and 90 days | Recruiting |
| 29 | Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19 | NCT04632706 | MedinCell S.A  MAC Clinical Research | United Kingdom | Interventional (Randomized, double blinded) | 24 | * Ivermectin * Placebo | • Pharmacokinetic concentrations:  - Maximum Plasma Concentration [Cmax]  - Time to Reach Cmax [Tmax]  - Trough Plasma Concentration [Ctrough]  - Area under the plasma concentration-time curve from zero to 24 hours [AUC0-24h]  - Area under the plasma concentration-time curve from zero to 48 hours [AUC0-48h  - Average Plasma Concentration at steady state [Cavg ss]  - Apparent Terminal Half-Life [T1/2]  - Number of participants with treatment emergent adverse events (TEAEs)  •Safety and Tolerability:  - Number of participants with abnormal electrocardiograms (ECG)  - Number of participants with abnormal clinical neurological exam  - Number of participants with abnormal urine and/or blood test  - Number of participants with abnormal physical exams | Recruiting |
| 30 | Trial of Combination Therapy to Treat COVID-19 Infection | NCT04482686 | ProgenaBiome  Topelia Therapeutics | United States | Interventional | 30 | * Ivermectin * Doxycycline * Hcl * Zinc * Vitamin D3 * Vitamin C | * Time to Non-Infectivity by RT-PCR * Time to Symptom progression in days * Time to Symptom improvement * Efficacy of Treatment as measured by Titer * Efficacy of Treatment as measured by RT-PCR, D-Dimer, ProCalcitonin, CRP, Ferritin, Liver Enzymes, CBC, Electrolyte Levels * Treatment Related Adverse Events | Recruiting |
| 31 | Risk Stratification of COVID-19 Using Urine Biomarkers | NCT04681040 | National Center for Global Health and Medicine, Japan | United States, Brazil, Denmark, Japan, Tokyo, Japan, Philippines | Observational, Prospective Cohort | 1000 | - | * Risk Stratification of COVID-19 Participants Using Urine Biomarkers * Prediction of COVID-19 Treatment by Urine LFABP * Increase of O2 support, hospital days, worsening of chest X-ray and CT, and survival rate, at 14 and/or 30 days * Comparison of Risk Stratification with Other Biomarkers | Recruiting |
| 32 | Ivermectin Nasal spray for COVID-19 patients | NCT04510233 | Tanta University | Egypt | Interventional | 60 | * Ivermectin (oral and nasal) | * PCR of SARS-Cov2 RNA | Not yet recruiting |
| 33 | Outpatient use of Ivermectin | NCT04530474 | Temple University | USA | Interventional | 200 | * Ivermectin | * Clinical improvement | Not yet recruiting |
| 34 | The (HD)IVACOV Trial (The High-Dose Ivermectin Against COVID-19 Trial) | NCT04712279 | Corpometria Institute | Brazil | Interventional | 294 | * Ivermectin * Hydroxychloroquine | * WHO clinical progression scale * Clinical Improvement * Time-to-recovery * Viral load * Positivity rate of rtPCR-SARS-CoV-2 * Duration of fatigue and anosmia * Overall duration of clinical manifestations * Proportion of subjects needing * Additional drugs or interventions * oxygen use * high-flow oxygen therapy or non-invasive ventilation * Proportion of hospitalizations * Proportion of mechanical ventilation use * Proportion of pressors use * Proportion of deaths * Proportion of post-COVID mental and physical symptoms * Proportion of post-COVID overall symptoms * Duration of new oxygen use, hospitalization and mechanical ventilation * Proportion of increased CRP, d-dimer and eosinophils * Proportion of decrease in ESR * Disease duration * Change in viral load from baseline to Day 5 | Not yet recruiting |
| 35 | Ivermectin and Nitazoxanide Combination Therapy for COVID-19 | NCT04360356 | Tanta University | Egypt | Interventional | 100 | * Ivermectin plus Nitazoxanide | * Number of Patients with COVID-19-negative PCR * Number of patients with improved respiratory rate * Number of patients with improved PaO2 * Number of patients with normalized Serum IL6 * Number of patients with normalized Serum TNFα * Number of patients with normalized Serum iron * Number of patients with normalized Serum ferritin * Number of patients with normalized PT-INR * Number of patients with normalized complete blood count, * Mortality rate among treated patients | Not yet recruiting |
| 36 | Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19 | NCT04551755 | Bangladesh Medical Research Council (BMRC | Bangladesh | Interventional | 188 | * Ivermectin and Doxycycline * Placebo | * Time to outcome measure of fever (<100.40F)and cough * Negative RT-PCR test on day 5 of treatment | Not yet recruiting |
| 37 | Safety and efficacy of low dose aspirin/ivermectin combination therapy for treatment of COVID-19 patients (IVCOM) | NCT04768179 | * Makarere University * Ministry of Health, Uganda * Mbarara University of Science and Technology * Joint Clinical Research Center | Uganda | Interventional | 490 | * Ivermectin * ASA * Standard of therapy | * SARS COV 2 Viral clearance * World Health Organization COVID-19 ordinal improvement score * Clinical recovery * Spectrum and severity of adverse events * Maximum Plasma concentration * Minimum Plasma concentration * Area Under the Curve | Not yet recruiting |
| 38 | Effectiveness and Safety of Ivermectin for the Prevention of Covid 19 Infection in Colombian Health Personnel | NCT04527211 | Javeriana University | Colombia | Interventional | 550 | * Ivermectin | * Clinical development of covid-19 disease during the intervention period * Seroconversion * Hospitalization requirement * Intensive Care Unit Requirement * Safety of the intervention | Not yet recruiting |
| 39 | New Antiviral Drugs for Treatment of COVID-19 | NCT04392427 | Mansoura University | Egypt | Interventional | 100 | * Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days | * Negative test result for COVID-19 | Not yet recruiting |
| 40 | Study the efficacy and therapeutic safety of Ivermectin (SAINTBO) | NCT04836299 | * Universidad Mayor de San Simón * Barcelona Institute for Global Health * Université Catholique de Louvain | Bolivia | Interventional | 90 | * Ivermectin * Placebo | * Evolution of viral load * Clinical remission * Clinical signs of toxicity * Need for supplemental oxygen * Hospital stay * Need for mechanical ventilation | Not yet recruiting |
| 41 | Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms | NCT04407507 | Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. | - | Interventional | 66 | * Ivermectin * Placebo | * Participants with a disease control status defined as no disease progression to severe | Not yet recruiting |
| 42 | Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic | NCT04460547 | Qassim University | - | Observational, Retrospective Cohort | 200 | * Convalescent Plasma Transfusion * Hydroxychloroquine * DAS181 * Ivermectin, * Interferon Beta-1A | * Geographical distribution of the interventional and observational studies * Monthly Research study completion rate as per geographic distribution of the Research * Statistical correlation of the interventional, Observational, drug based interventional, diagnostic test based interventional and device based interventional studies | Not yet recruiting |